Navigation Links
Pharmasset Reports Fiscal Year End 2007 Financial Results
Date:12/31/2007

PRINCETON, N.J., Dec. 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported audited financial results for the fiscal year ended September 30, 2007. Pharmasset reported a net loss attributable to common stockholders of $6.8 million, or $0.46 per share, as compared to a net loss attributable to common stockholders of $12.4 million, or $1.19 per share for the same period in 2006.

Revenues were $22.0 million during the fiscal year 2007, primarily consisting of development milestones and the amortization of payments received from Roche from the hepatitis C virus (HCV) collaboration agreement that were previously recorded as deferred revenue. Revenues for the same period in 2006 were $5.4 million. This $16.6 million increase from the year ago period was primarily due to the receipt of milestone payments from Roche totaling $20.0 million during fiscal year 2007. Investment income was $2.5 million during fiscal year 2007 compared to $1.7 million during fiscal year 2006. This $0.8 million increase was due to higher average invested cash balances during 2007.

Total costs and expenses for the fiscal year ended September 30, 2007 were $29.5 million as compared to $18.4 million for the same period in 2006. The increased operating expenses for fiscal year 2007 were primarily the result of an increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B virus (HBV) infection, as well as drug discovery, non-cash stock compensation and depreciation expenses.

At September 30, 2007, Pharmasset held $68.7 million in cash and cash equivale
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Revolutionary Science, ... automatic colony counter, announced today that they have expanded ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... sophistication are especially useful in food microbiology and pharmaceutical ... an updated look. A bright white enclosure with ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Vital ... the University of California, San Diego for a joint ... bearing Gravitic™ MRI (Magnetic Resonance Imaging) with that of ... for its continued pursuit of improved healthcare by combining ... MRI is an extremely valuable tool for evaluating pathological ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 PathoGenetix, ... rapid bacterial strain typing, announced today that it has ... pathogenic E. coli strains obtained from the Centers for ... Sequence Scanning™ (GSS™) technology. The findings are detailed in ... of the American Society for Microbiology in Denver on ...
(Date:5/20/2013)... MELBOURNE, Australia , May 20, 2013 ... of Agriculture,s (USDA) Agricultural Research Service (ARS) in ... market opportunity , Trials to begin ... Australian drug delivery technology company Phosphagenics Limited ... U.S. Department of Agriculture,s (USDA) Agricultural Research Service (ARS) ...
Breaking Biology Technology:Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... , MINNEAPOLIS, Aug. 4 Techne Corporation,s (Nasdaq: ... June 30, 2009 decreased 6.9% to $25.4 million or $.68 per ... for the quarter ended June 30, 2008. For the fiscal year ... $105.2 million or $2.78 per diluted share compared with $103.6 million ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) ... from the U.S. Patent and Trademark Office for its U.S. ... Allowed claims cover a family of cyclic compounds that bind ... heart failure drug candidate. Palatin expects the patent will issue ...
... molecule-sized pores are one step closer to replacing the ... of academic researchers is reporting. Writing this week ... membranes, ability to separate molecules in a mixture is ... processing (RTP). By heating the membranes from room temperature ...
Cached Biology Technology:Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 5Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 6Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009 7Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 2Rapid heating prepares energy-saving zeolite for greater role in industrial separations 3Rapid heating prepares energy-saving zeolite for greater role in industrial separations 4
(Date:5/19/2013)... of California, Davis have engineered a strain of photosynthetic ... They report their findings today at the 113th General ... this work, we used synthetic biology approaches to probe ... light energy for growth) cyanobacterial metabolism for the ability ... lead researcher on the study. He is part ...
(Date:5/17/2013)... (May 18, 2013) The AGA Research Foundation announced ... the relationship between the gut microbiota, one of today,s ... disease. , The AGA Research Awards Panel selected ... Massachusetts General Hospital and Harvard Medical School, Boston, as ... Dr. Chan will receive $25,000 of funding, commencing in ...
(Date:5/17/2013)... Shenzhen, China---- Why Tibetan antelope can live at ... a collaborative research published in Nature Communications ... institutes provide evidence that some genetic factors may ... highland environments. The data in this work will ... and the biology of other ruminant species. , ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... a lack of international protections have put several species of ... illegal logging, according to a policy forum paper in the ... 48 species of rosewood ( Dalbergia ) are found nowhere ... Barrett, the lead author on the May 27 article. ...
... Jon Chase once worked in a lab that set up small ... "We would try to duplicate pond communities with a given experimental ... each pond, and five of these species, and eight of the ... of that and ,sproing, every replicate would do its own thing ...
... from four U.S. universities have created a way to ... 2-D and 3-D structures that could find use in ... a child might use Lego blocks to build 3-D ... using the new chemical self-assembly method to build complex ...
Cached Biology News:Rosewood trees face extinction amid Madagascar's chaos 2The great pond experiment: Regional vs. local biodiversity 2The great pond experiment: Regional vs. local biodiversity 3Optical Legos: Building nanoshell structures 2
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... Antibody, Catalog #2062, 40 ul Histone Deacetylase ... Histone Deacetylase 4 (HDAC4) Antibody, Catalog #2072, ... Catalog #2082, 40 ul Histone Deacetylase 6 ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: